Background. Thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) remains the only approved medication for acute ischemic stroke, but incurs significant bleeding risks. Therefore, approaches to combine lower doses of thrombolytic therapy with other effective drugs aim at improving efficacy and reducing bleeding rates. We examined the safety and therapeutic effects of various dosings of rtPA, either alone or combined with glycoprotein VI-Fc fusion protein (GPVI-Fc, Revacept) on experimental stroke in mice. Methods and results. The effect of filament-induced intracerebral thrombus formation and embolization was investigated after a one-hour occlusion of the middle cerebral artery. In accordance with previous studies, treatment with 10 mg/kg rtPA significantly improved functional outcome, cerebral infarct size and edema, but also resulted in markedly increased intracranial bleeding volumes. In contrast, low doses of rtPA (0.1 or 0.35 mg/kg body weight) did not change outcome parameters. However, addition of 1 mg/kg Revacept to 0.35 mg/kg rtPA led to improved reperfusion compared to rtPA alone. Moreover, these combined treatments resulted in improved grip strength, compared to the respective dose of rtPA alone. Infarct-surrounding edema improved after combined treatments, but not after respective single rtPA dosings. Intracranial bleeding volumes were below controls after all low-dose rtPA therapies, given either alone or combined with Revacept. Conclusions. In contrast to using the equally effective full dose of rtPA, intracranial bleeding was not increased by low-dose rtPA combined with Revacept. Therefore, addition of Revacept to low-dose rtPA does not incur safety risks, but improves efficacy of treatment.
Glycoprotein VI, Middle cerebral artery occlusion, Platelet aggregation, Stroke
Financial support: This study was supported by a grant from the Bavarian
Research Foundation (Bayerische Forschungsstiftung), grant
Martin Ungerer AdvanceCOR GmbH – Procorde Fraunhofer Str. 9a 82152 Martinsried, Germany firstname.lastname@example.org; Meinrad Gawaz University of Tübingen Otfried-Müller-Str. 10 72076 Tübingen, Germany email@example.com
We acknowledge the excellent technical assistance of Isabel Fodor.
Share this Article
Related Content In Thrombosis
A Review of the Past, Present and Future of Cancer-associated Thrombosis Management
Heart International. 2022;16(2):117–23 DOI: https://doi.org/10.17925/HI.2022.16.2.117
In this article, we review prior and recent landmark studies that have directed the treatment of cancer-associated thrombosis (CAT), discuss specific factors that influence anticoagulant choice, and explore ongoing trials that may impact treatment in the future. Older data estimated less than 1% of patients with malignancy developed venous thromboembolism (VTE), but more recent data […]
Andexanet Alfa and its Clinical Application
Heart International. 2020;14(1):20-3 DOI: https://doi.org/10.17925/HI.2020.14.1.20
The factor Xa (FXa) inhibitors apixaban, rivaroxaban and edoxaban, together with the thrombin inhibitor dabigatran, are collectively referred to as non-vitamin K antagonist (or direct) oral anticoagulants (NOACs). FXa inhibitors are widely used for stroke prevention in patients with nonvalvular atrial fibrillation,1 and for the treatment and prevention of deep vein thrombosis and pulmonary embolism.2,3 In patients […]
Improved Dosing and Administration of Rivaroxaban when Prescribed by a Cardiologist
Heart International. 2019;13(1):24–7 DOI: https://doi.org/10.17925/HI.2019.13.1.24
Rivaroxaban is a direct factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF), treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). Furthermore, it is prescribed for risk reduction and prophylaxis for DVT and PE following hip or knee replacement surgery and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!